Clinical Trials Logo

Clinical Trial Summary

The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)


Clinical Trial Description

This is a multi-site randomized placebo controlled trial of Bydureon in patients with type I diabetes (T1D) of at least 2 years duration who may or may not still have detectable levels of C-peptide during a mixed meal tolerance test (MMTT). Bydureon is a recently approved long acting form of Exenatide. Because of the lack of safety data for Bydureon in children, we propose to conduct the trial in adults (>18 yrs.).

Both the subject and the study personnel will be blinded to treatment assignment. The randomization will be done, 1;1, by the coordinating site (at Yale). As a secondary analysis, we propose to determine whether the presence of residual insulin production modifies the drug effect. To do this, we plan to stratify patients for randomization on the basis of detectable C-peptide levels. We will therefore wait for the results of the C-peptide levels from the enrollment MMTT prior to randomization. The study investigators will not be told in which stratum the patient is being randomized and will be blinded to the C-peptide results of the MMTT until the conclusion of the study.

Note: The primary and study completion dates were changed 4/2016 to reflect an extension of the recruitment and accrual periods. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01928329
Study type Interventional
Source Yale University
Contact
Status Completed
Phase Phase 2
Start date September 2013
Completion date August 2019

See also
  Status Clinical Trial Phase
Completed NCT05160142 - Diabetes Inspired Culinary Education Early Phase 1
Withdrawn NCT05035368 - Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes Phase 2
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00999375 - Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF) Phase 2
Completed NCT04279613 - A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Phase 1
Not yet recruiting NCT02117518 - Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients N/A
Withdrawn NCT01477476 - Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes Phase 2
Terminated NCT01308437 - Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics Phase 3
Terminated NCT01652911 - A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation Phase 1/Phase 2
Completed NCT06242548 - How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude N/A
Completed NCT00351650 - Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan N/A
Withdrawn NCT00361608 - Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device N/A
Terminated NCT03653533 - Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump N/A
Completed NCT00340639 - Management of Type 1 Diabetes Among Adolescents N/A
Completed NCT02634216 - Effects of Capros in Patients With Type-1 Diabetes N/A
Completed NCT02002130 - The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes Phase 1
Withdrawn NCT01623388 - Epigenetic Modifications of Diabetes Mellitus Type I N/A
Completed NCT02612493 - Obesity and Metabolic Surgery in Patients With Type I Diabetes N/A
Completed NCT01843114 - Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects N/A
Withdrawn NCT01398670 - Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics Phase 3